Melflufen is a novel peptide–drug conjugate that rapidly delivers a cytotoxic payload into
tumor cells. It has emerged as a potential new multiple myeloma treatment, particularly for …

Multiple myeloma (MM) is still an incurable hematologic malignancy. Although new
therapeutic strategies have been developed to target different pathways in malignant cells …

Daratumumab is a human anti-CD38 monoclonal antibody used in the treatment of
refractory and relapsed multiple myeloma. We investigated the efficacy and safety of …

ABSTRACT ONC201, founding member of the imipridone class of small molecules, is
currently being evaluated in advancer cancer clinical trials. We explored single agent and …

The availability of novel therapies for the treatment of multiple myeloma has had a dramatic
impact on the depth of response that can be expected on initial treatment. Despite these …

The oncolytic reovirus (RV) has demonstrated clinical efficacy and minimal toxicity in a
variety of cancers, including multiple myeloma (MM). MM is a malignancy of plasma cells …

Multiple myeloma (MM) is still an incurable plasma cell tumor. Natural killer (NK) cells are
characterized by efficient anti-tumor activity, and their activity is one basis of cancer …

Median overall survival (OS) has improved for patients with newly diagnosed multiple
myeloma (NDMM), but prognosis varies depending on baseline patient characteristics …

High‐dose melphalan followed by autologous haematopoietic stem cell transplantation is
widely used in newly diagnosed multiple myeloma (MM) patients as upfront therapy …

目的: 初步探讨多发性骨髓瘤(MM) 中NK 细胞, Treg 细胞表达水平与疾病进展及预后的关系.
方法: 收集48 例初诊MM 患者治疗前及3~ 4 个疗程治疗后外周血标本, 采用流式细胞仪测定 …